Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

We noted a vitamin D deficiency in 95% of the patients at the initial T0 baseline, with this type of deficiency being found in many degenerative diseases, mostly associated with the frailty syndrome in the elderly population.

Source: 3.3. Vitamin Supplementation. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

All patients were carefully screened, starting from the 5-2-1 status (5 doses of levodopa daily, with 2 h off and 1 h of dyskinesia): the main inclusion criteria to define oral therapy inefficacy in patients presenting APD.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Levodopa-Carbidopa-Entacapone Intestinal Gel for Advanced Parkinson’s Disease: Results from a Monocentric Study Evaluating Both Motor and Non-Motor Manifestations

Study design awaiting verification · Biomedicines · 2025

Original publication title

Levodopa: Carbidopa: Entacapone Intestinal Gel for Advanced Parkinson’s Disease: Results from a Monocentric Study Evaluating Both Motor and Non-Motor Manifestations

Mihaiela Lungu; Violeta Diana Oprea; Luminița Lăcrămioara Apostol; Eva Maria Elkan; Ana Maria Ionescu; Anca Tudor; Lucian Andrei Zaharia

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Parkinson’s disease (PD) in advanced stages becomes, over time, a significant challenge, as oral medication becomes ineffective, and it may become necessary to switch to device-assisted therapy (DAT). This should be personalized according to the stage of the disease, the cognitive status of the patients, the association of frailty syndrome or other comorbidities, the support in care from the family, etc. Levodopa: carbidopa: entacapone intestinal gel can significantly improve the status of patients, provided that they are correctly selected for this type of treatment.

Materials and Methods:

We conducted a single-center prospective study including 20 advanced PD patients, who received a levodopa: carbidopa: entacapone gel through an intestinal pump, within the Parkinson’s Disease Multimodal Treatment Center of the Neurology Clinic of the “St. Ap. Andrew” County Emergency Clinical Hospital in Galați, Romania. The evaluations were performed at baseline (T0), after intestinal pump insertion (T1), and 6 months after the procedure (T2).

Results:

In the study group, the administration of the levodopa: carbidopa: entacapone intestinal gel, using the device for intestinal administration, had significant benefits, especially for motor symptoms. The periods of off, no-on, freezing, sudden-off, as well as dyskinesia and morning akinesia, were significantly reduced. Among the non-motor symptoms, depression and sleep disorders improved, with no changes in cognitive status and psychotic disorders.

Conclusions:

Adding new data for the use of device-assisted therapy in advanced PD, our study also highlights the need to further research this challenging patient profile.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Parkinson’s disease (PD) in advanced stages becomes, over time, a significant challenge, as oral medication becomes ineffective, and it may become necessary to switch to device-assisted therapy (DAT). This should be personalized according to the stage of the disease, the cognitive status of the patients, the association of frailty syndrome or other comorbidities, the support in care from the family, etc. Levodopa: carbidopa: entacapone intestinal gel can significantly improve the status of patients, provided that they are correctly selected for this type of treatment.

Source: Background

Abstract: Results

In the study group, the administration of the levodopa: carbidopa: entacapone intestinal gel, using the device for intestinal administration, had significant benefits, especially for motor symptoms. The periods of off, no-on, freezing, sudden-off, as well as dyskinesia and morning akinesia, were significantly reduced. Among the non-motor symptoms, depression and sleep disorders improved, with no changes in cognitive status and psychotic disorders.

Source: Results

Abstract: Conclusions

Adding new data for the use of device-assisted therapy in advanced PD, our study also highlights the need to further research this challenging patient profile.

Source: Conclusions
Authors’ abstract

Background:

Parkinson’s disease (PD) in advanced stages becomes, over time, a significant challenge, as oral medication becomes ineffective, and it may become necessary to switch to device-assisted therapy (DAT). This should be personalized according to the stage of the disease, the cognitive status of the patients, the association of frailty syndrome or other comorbidities, the support in care from the family, etc. Levodopa: carbidopa: entacapone intestinal gel can significantly improve the status of patients, provided that they are correctly selected for this type of treatment.

Materials and Methods:

We conducted a single-center prospective study including 20 advanced PD patients, who received a levodopa: carbidopa: entacapone gel through an intestinal pump, within the Parkinson’s Disease Multimodal Treatment Center of the Neurology Clinic of the “St. Ap. Andrew” County Emergency Clinical Hospital in Galați, Romania. The evaluations were performed at baseline (T0), after intestinal pump insertion (T1), and 6 months after the procedure (T2).

Results:

In the study group, the administration of the levodopa: carbidopa: entacapone intestinal gel, using the device for intestinal administration, had significant benefits, especially for motor symptoms. The periods of off, no-on, freezing, sudden-off, as well as dyskinesia and morning akinesia, were significantly reduced. Among the non-motor symptoms, depression and sleep disorders improved, with no changes in cognitive status and psychotic disorders.

Conclusions:

Adding new data for the use of device-assisted therapy in advanced PD, our study also highlights the need to further research this challenging patient profile.

Publication and source details

Original title: Levodopa: Carbidopa: Entacapone Intestinal Gel for Advanced Parkinson’s Disease: Results from a Monocentric Study Evaluating Both Motor and Non-Motor Manifestations

Mihaiela Lungu; Violeta Diana Oprea; Luminița Lăcrămioara Apostol; Eva Maria Elkan; Ana Maria Ionescu; Anca Tudor; Lucian Andrei Zaharia

Biomedicines · 2025

* Correspondence: diana.v.oprea@gmail.com (V.D.O.); zaharia.andreilucian@gmail.com (L.A.Z.); Tel.: +45-51777312 (V.D.O.)© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).This research received no external funding. The APC was funded by the Faculty of Medicine and Pharmacy “Dunarea de Jos” University of Galati, Romania, with no influence on the research or the content of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:00:59.049781+00:00

DOI: 10.3390/biomedicines13092191 · PMC12467503